Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of KRM Ayurveda
Quarter-by-quarter operating performance
Financials of KRM Ayurveda
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 89 | 67 | 77 | 102 |
| Expenses + | 78 | 60 | 57 | 71 |
| Operating Profit | 11 | 8 | 19 | 30 |
| OPM % | 13% | 11% | 25% | 30% |
| Other Income + | 0 | 0 | 0 | 1 |
| Interest | 1 | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 | 1 |
| Profit before tax | 10 | 5 | 16 | 27 |
| Tax % | 25% | 28% | 26% | 25% |
| Net Profit + | 8 | 3 | 12 | 20 |
| EPS in Rs | 5,066.67 | 2,273.33 | 806.67 | 9.46 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of KRM Ayurveda
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.15 | 0.15 | 0.15 | 21 |
| Reserves | 8 | 12 | 24 | 93 |
| Borrowings + | 20 | 23 | 31 | 0 |
| Other Liabilities + | 11 | 9 | 12 | 8 |
| Total Liabilities | 39 | 44 | 67 | 122 |
| Fixed Assets + | 23 | 23 | 27 | 26 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 38 |
| Other Assets + | 16 | 21 | 40 | 58 |
| Total Assets | 39 | 44 | 67 | 122 |
Financials of KRM Ayurveda
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 4 | -1 | -0 | 1 |
| Cash from Investing Activity + | -23 | -0 | -4 | -30 |
| Cash from Financing Activity + | 19 | 1 | 6 | 37 |
| Net Cash Flow | 0 | 0 | 2 | 7 |
| Free Cash Flow | -20 | -1 | -5 | 0 |
| CFO/OP | 36% | 33% | 14% | 29% |
Financials of KRM Ayurveda
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 32 | 30 | 58 | 82 |
| Inventory Days | 13 | 53 | 296 | 225 |
| Days Payable | 100 | 141 | 205 | 80 |
| Cash Conversion Cycle | -55 | -58 | 149 | 227 |
| Working Capital Days | 9 | 48 | 64 | 280 |
| ROCE % | 22% | 42% | 35% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…